Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)
Condition(s):Diabetes Mellitus, Type 2Last Updated:August 13, 2019Unknown status
Hide Studies Not Open or Pending
Condition(s):Diabetes Mellitus, Type 2Last Updated:August 13, 2019Unknown status
Condition(s):ObesityLast Updated:February 13, 2024Completed
Condition(s):HypercholesterolemiaLast Updated:April 13, 2021Unknown status
Condition(s):Major Adverse Limb Events; Major Adverse Cardiovascular Events; Peripheral Artery Disease; Critical Limb Ischemia; Hemodynamic MeasureLast Updated:March 19, 2024Recruiting
Condition(s):Coronary Artery DiseaseLast Updated:July 18, 2023Completed
Condition(s):Hypercholesterolemia; Type 2 Diabetes; HypertensionLast Updated:June 1, 2011Terminated
Condition(s):Metabolic SyndromeLast Updated:October 26, 2016Withdrawn
Condition(s):Barrett’s Oesophagus; Oesophageal VaricesLast Updated:January 10, 2022Completed
Condition(s):Coronary Artery Disease; Coronary RestenosisLast Updated:January 24, 2007Unknown status
Condition(s):Heart Failure; Heart Failure NYHA Class III; Heart Failure NYHA Class II; Heart Failure NYHA Class IVLast Updated:January 30, 2020Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.